amlodipine has been researched along with Elevated Cholesterol in 33 studies
Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.
amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 9.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 9.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| "The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance." | 9.11 | Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004) |
| "This short-term, open-label study examined whether statin therapy had a synergistic effect on the BP-lowering efficacy of perindopril/amlodipine in a subgroup of patients in the PERSPECTIVA study with concomitant hypertension and hypercholesterolemia, with or without statin at baseline." | 7.85 | Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. ( Radchenko, G; Sirenko, Y, 2017) |
| " This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome." | 7.75 | Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009) |
| "Simvastatin is an HMG-CoA reductase inhibitor that is metabolized by the cytochrome P450 (CYP) 3A4." | 6.71 | Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ( Hayashi, H; Kosuge, K; Nishio, S; Ohashi, K; Uchida, S; Watanabe, H, 2005) |
| "BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks." | 5.43 | Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination? ( Wang, M; Zeng, R; Zhang, L, 2016) |
| "Hypercholesterolemia is a common accompaniment of atherosclerosis and may be associated with cardiac hypertrophy." | 5.35 | Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. ( Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W, 2009) |
| " This study was conducted to compare the efficacy and tolerability of the combination therapies telmisartan/amlodipine + rosuvastatin, telmisartan/amlodipine, and telmisartan + rosuvastatin in patients with hypercholesterolemia and hypertension." | 5.30 | Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study. ( Ahn, JC; Cha, DH; Cho, SK; Jeon, DW; Kim, KH; Kim, SY; Kim, TS; Kim, WS; Kim, YJ; Lee, HC; Oh, YS; Park, DG; Park, SH; Rha, SW; Rhee, MY; Sung, KC; Yoo, BS; Yoo, KD; Yoon, MH; Yoon, YW, 2019) |
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 5.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| "To investigate the efficacy and safety of single-pill amlodipine/atorvastatin therapy for the simultaneous treatment of hypertension (HTN) and dyslipidemia in African Americans." | 5.13 | Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial. ( Bruschi, P; Ferdinand, KC; Flack, JM; Jamieson, MJ; Saunders, E; Shi, H; Tarasenko, L; Victor, R; Watson, K, 2008) |
| "Our aim in this study was to investigate the changes of serum high-sensitive C-reactive protein (hs-CRP) and uric acid (UA), and evaluate the synergistic effect of amlodipine and atorvastatin on blood pressure and left ventricular remodeling in hypertensive patients with primary hypercholesterolemia." | 5.13 | Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia. ( Chen, YD; Ge, CJ; Hu, SJ; Ji, Y; Lu, SZ; Wu, XF, 2008) |
| "The aim of this study was to evaluate the effect of the amlodipine-atorvastatin combination on plasma tissue plasminogen activator (t-PA) and plasminogen activator inhibitor type 1 (PAI-1) activity in hypercholesterolemic, hypertensive patients with insulin resistance." | 5.11 | Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance. ( Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Mugellini, A; Rinaldi, A; Zoppi, A, 2004) |
| "The primary objective of this study was to determine whether combination therapy with valsartan 160 mg plus hydrochlorothiazide (HCTZ) 25 mg OD would be more effective than monotherapy with amlodipine 10 mg OD in reducing systolic blood pressure (SBP) in patients with moderate (stage II) hypertension and > or =1 other cardiovascular risk factor or concomitant condition." | 5.11 | Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. ( Bönner, G; Heintz, D; Kandra, A; Khder, Y; Malacco, E; Ruilope, LM, 2005) |
| "The Antihypertensive and Lipid-Lowering high-risk hypertensive participants, ages > or = 55 years, designed to determine whether the incidence of fatal and nonfatal coronary heart disease (CHD) and combined cardiovascular events (fatal and nonfatal CHD, revascularization surgery, angina pectoris, congestive heart failure, and stroke) differs between diuretic (chlorthalidone) treatment and three alternative antihypertensive therapies: a calcium channel blocker (amlodipine), an ACE inhibitor (lisinopril), and an alpha-adrenergic blocker (doxazosin)." | 5.09 | Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ( Barzilay, JI; Basile, JN; Ciocon, JO; Davis, BR; Goff, DC; Jones, CL; Randall, OS; Sweeney, ME, 2001) |
| "This short-term, open-label study examined whether statin therapy had a synergistic effect on the BP-lowering efficacy of perindopril/amlodipine in a subgroup of patients in the PERSPECTIVA study with concomitant hypertension and hypercholesterolemia, with or without statin at baseline." | 3.85 | Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia. ( Radchenko, G; Sirenko, Y, 2017) |
| "Patients with mild/moderate hypertension and hypercholesterolemia, at high-/very high-CV risk, received lisinopril-amlodipine (10/5, 20/5 or 20/10 mg/day) plus rosuvastatin (10 or 20 mg/day)." | 3.83 | Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients. ( Gaszner, B; Hild, G; Kónyi, A; Sárszegi, Z, 2016) |
| " This subanalysis of the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points (CAPABLE) trial studied attainment of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) and the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) goals by 8 flexibly titrated doses (5/10-10/80 mg) of amlodipine/atorvastatin single pill in 494 African Americans with hypertension and dyslipidemia, according to the presence of diabetes +/- the metabolic syndrome." | 3.75 | Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus. ( Ferdinand, KC; Flack, JM; Jamieson, MJ; Kursun, A; Saunders, E; Shi, H; Victor, R; Watson, K, 2009) |
| "We investigated the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/CRP) transgenic mice." | 3.73 | Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice. ( de Maat, M; Emeis, J; Havekes, L; Jukema, W; Maas, A; Offerman, E; Princen, H; Szalai, A; Trion, A; van der Laarse, A, 2006) |
"Eligible patients had treated or untreated hypertension, >or=3 additional cardiovascular risk factors, and baseline total cholesterol| 2.75 | Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study. ( Al Khadra, A; Erdine, S; Kim, JH; Lopez, AP; Sutradhar, S; Westergaard, M; Yunis, C; Zamorano, J, 2010) | |
| "Simvastatin is an HMG-CoA reductase inhibitor that is metabolized by the cytochrome P450 (CYP) 3A4." | 2.71 | Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension. ( Hayashi, H; Kosuge, K; Nishio, S; Ohashi, K; Uchida, S; Watanabe, H, 2005) |
| "BACKGROUND Is the timing of dosing for amlodipine and atorvastatin important with regard to therapeutic efficacy? To answer this question, we designed an outpatient, practice-based, case-control study lasting 8 weeks." | 1.43 | Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination? ( Wang, M; Zeng, R; Zhang, L, 2016) |
| "Hypercholesterolemia is a common accompaniment of atherosclerosis and may be associated with cardiac hypertrophy." | 1.35 | Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine. ( Kang, BY; Mehta, JL; Palade, P; Sharma, SG; Wang, W, 2009) |
| "Amlodipine reduced the increase in oxidative stress by inhibiting excessive MDA production." | 1.32 | Amlodipine and glutathione cycle in hypercholesterolaemia. ( Bayindir, O; Habif, S; Mutaf, I; Ozmen, D; Parildar, Z; Turgan, N; Uysal, A, 2004) |
| "Hypercholesterolemia is associated with AT1-receptor upregulation, endothelial dysfunction, and increased NADH-dependent vascular O2*- production." | 1.30 | Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. ( Böhm, M; Bräsen, JH; Griendling, KK; Harrison, DG; Heitzer, T; Macharzina, R; Meinertz, T; Münzel, T; Nickenig, G; Schulz, E; Skatchkov, M; Stasch, JP; Warnholtz, A, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (6.06) | 18.2507 |
| 2000's | 14 (42.42) | 29.6817 |
| 2010's | 16 (48.48) | 24.3611 |
| 2020's | 1 (3.03) | 2.80 |
| Authors | Studies |
|---|---|
| Cicero, AFG | 1 |
| Fogacci, F | 1 |
| Rizzoli, E | 1 |
| Giovannini, M | 1 |
| D'Addato, S | 1 |
| Borghi, C | 1 |
| Muñoz, D | 1 |
| Uzoije, P | 1 |
| Reynolds, C | 1 |
| Miller, R | 1 |
| Walkley, D | 1 |
| Pappalardo, S | 1 |
| Tousey, P | 1 |
| Munro, H | 1 |
| Gonzales, H | 1 |
| Song, W | 1 |
| White, C | 1 |
| Blot, WJ | 1 |
| Wang, TJ | 1 |
| Schaffer, AL | 1 |
| Buckley, NA | 1 |
| Pearson, SA | 1 |
| Lee, HY | 1 |
| Kim, SY | 2 |
| Choi, KJ | 1 |
| Yoo, BS | 2 |
| Cha, DH | 2 |
| Jung, HO | 1 |
| Ryu, DR | 1 |
| Choi, JH | 1 |
| Lee, KJ | 1 |
| Park, TH | 1 |
| Oh, JH | 1 |
| Kim, SM | 1 |
| Choi, JY | 1 |
| Kim, KH | 2 |
| Shim, J | 1 |
| Kim, WS | 2 |
| Choi, SW | 1 |
| Park, DG | 2 |
| Song, PS | 1 |
| Hong, TJ | 1 |
| Rhee, MY | 2 |
| Rha, SW | 2 |
| Park, SW | 1 |
| Gupta, A | 1 |
| Mackay, J | 1 |
| Whitehouse, A | 1 |
| Godec, T | 1 |
| Collier, T | 1 |
| Pocock, S | 1 |
| Poulter, N | 1 |
| Sever, P | 1 |
| Kim, TS | 1 |
| Sung, KC | 1 |
| Yoon, MH | 1 |
| Lee, HC | 1 |
| Kim, YJ | 1 |
| Ahn, JC | 1 |
| Park, SH | 1 |
| Yoo, KD | 1 |
| Jeon, DW | 1 |
| Yoon, YW | 1 |
| Cho, SK | 1 |
| Oh, YS | 1 |
| Simon, A | 1 |
| Dézsi, CA | 1 |
| Simonyi, G | 1 |
| Ferenci, T | 1 |
| Kónyi, A | 1 |
| Sárszegi, Z | 1 |
| Hild, G | 1 |
| Gaszner, B | 1 |
| Zeng, R | 1 |
| Wang, M | 1 |
| Zhang, L | 1 |
| Sirenko, Y | 1 |
| Radchenko, G | 1 |
| Kang, BY | 1 |
| Wang, W | 1 |
| Palade, P | 1 |
| Sharma, SG | 1 |
| Mehta, JL | 1 |
| Ferdinand, KC | 2 |
| Flack, JM | 2 |
| Saunders, E | 2 |
| Victor, R | 2 |
| Watson, K | 2 |
| Kursun, A | 1 |
| Jamieson, MJ | 2 |
| Shi, H | 2 |
| Zamorano, J | 1 |
| Erdine, S | 1 |
| Lopez, AP | 1 |
| Kim, JH | 1 |
| Al Khadra, A | 1 |
| Westergaard, M | 1 |
| Sutradhar, S | 1 |
| Yunis, C | 1 |
| Hussein, MA | 1 |
| Chapman, RH | 1 |
| Benner, JS | 1 |
| Tang, SS | 1 |
| Solomon, HA | 1 |
| Joyce, A | 1 |
| Foody, JM | 1 |
| Derosa, G | 2 |
| Maffioli, P | 1 |
| Tho, LM | 1 |
| Bose, N | 1 |
| Robertson, L | 1 |
| Bhattacharya, S | 1 |
| McClue, L | 1 |
| Anderson, L | 1 |
| Fraser, E | 1 |
| Graham, K | 1 |
| Yosef, H | 1 |
| Lumsden, G | 1 |
| Salehi, I | 1 |
| Mohammadi, M | 1 |
| Mirzaei, F | 1 |
| Soufi, FG | 1 |
| Wald, DS | 1 |
| Morris, JK | 1 |
| Wald, NJ | 1 |
| Ostroumova, OD | 1 |
| Neumaier, J | 1 |
| Felmeden, DC | 1 |
| Blann, AD | 1 |
| Spencer, CG | 1 |
| Beevers, DG | 1 |
| Lip, GY | 1 |
| Fogari, R | 1 |
| Lazzari, P | 1 |
| Zoppi, A | 1 |
| Fogari, E | 1 |
| Rinaldi, A | 1 |
| Mugellini, A | 1 |
| Mutaf, I | 1 |
| Habif, S | 1 |
| Turgan, N | 1 |
| Parildar, Z | 1 |
| Ozmen, D | 1 |
| Bayindir, O | 1 |
| Uysal, A | 1 |
| Ruilope, LM | 1 |
| Malacco, E | 1 |
| Khder, Y | 1 |
| Kandra, A | 1 |
| Bönner, G | 1 |
| Heintz, D | 1 |
| Nishio, S | 1 |
| Watanabe, H | 1 |
| Kosuge, K | 1 |
| Uchida, S | 1 |
| Hayashi, H | 1 |
| Ohashi, K | 1 |
| Akira, K | 1 |
| Amano, M | 1 |
| Okajima, F | 2 |
| Hashimoto, T | 1 |
| Oikawa, S | 1 |
| Trion, A | 1 |
| de Maat, M | 1 |
| Jukema, W | 1 |
| Maas, A | 1 |
| Offerman, E | 1 |
| Havekes, L | 1 |
| Szalai, A | 1 |
| van der Laarse, A | 1 |
| Princen, H | 1 |
| Emeis, J | 1 |
| Tarasenko, L | 1 |
| Bruschi, P | 1 |
| Ge, CJ | 1 |
| Lu, SZ | 1 |
| Chen, YD | 1 |
| Wu, XF | 1 |
| Hu, SJ | 1 |
| Ji, Y | 1 |
| Warnholtz, A | 1 |
| Nickenig, G | 1 |
| Schulz, E | 1 |
| Macharzina, R | 1 |
| Bräsen, JH | 1 |
| Skatchkov, M | 1 |
| Heitzer, T | 1 |
| Stasch, JP | 1 |
| Griendling, KK | 1 |
| Harrison, DG | 1 |
| Böhm, M | 1 |
| Meinertz, T | 1 |
| Münzel, T | 1 |
| Cicco, G | 1 |
| van der Kleij, AJ | 1 |
| Stingi, GD | 1 |
| Tarallo, MS | 1 |
| Pirrelli, A | 1 |
| Barzilay, JI | 1 |
| Jones, CL | 1 |
| Davis, BR | 1 |
| Basile, JN | 1 |
| Goff, DC | 1 |
| Ciocon, JO | 1 |
| Sweeney, ME | 1 |
| Randall, OS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| The SCCS Polypill Pilot Trial[NCT02278471] | Phase 2 | 303 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study[NCT02899455] | Phase 3 | 146 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Randomized, Double-blind, Multi-center Phase III Clinical Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine and Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia[NCT03566316] | Phase 3 | 134 participants (Actual) | Interventional | 2015-11-24 | Completed | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| [NCT00000542] | Phase 3 | 0 participants | Interventional | 1993-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 109 |
| Polypill | 98 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 108 |
| Polypill | 90 |
polypill-percentage of pills taken, evaluated via pill counts (NCT02278471)
Timeframe: 2 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 98 |
polypill arm-evaluation via pill counts. (NCT02278471)
Timeframe: 12 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 86 |
polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 138 |
| Polypill | 131 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 133 |
| Polypill | 128 |
1 review available for amlodipine and Elevated Cholesterol
| Article | Year |
|---|---|
Effects of amlodipine plus atorvastatin association in hypertensive hypercholesterolemic patients.
Topics: Amlodipine; Antihypertensive Agents; Atorvastatin; Biomarkers; Blood Pressure; Cardiovascular Diseas | 2010 |
13 trials available for amlodipine and Elevated Cholesterol
| Article | Year |
|---|---|
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Comorbidity; Do | 2017 |
Long-term mortality after blood pressure-lowering and lipid-lowering treatment in patients with hypertension in the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow-up results of a randomised factorial trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Atorvastatin; | 2018 |
Efficacy and Tolerability of Telmisartan/Amlodipine and Rosuvastatin Coadministration in Hypertensive Patients with Hyperlipidemia: A Phase III, Multicenter, Randomized, Double-blind Study.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Double-Blind Method; Drug Combi | 2019 |
Design and rationale of a real-life study to compare treatment strategies for cardiovascular risk factors: the CRUCIAL study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorv | 2010 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular | 2012 |
A comparison of flow-mediated dilatation and von Willebrand factor as markers of endothelial cell function in health and in hypertension: relationship to cardiovascular risk and effects of treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes T
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atenolol; Brachial Artery; Card | 2003 |
Effect of amlodipine-atorvastatin combination on fibrinolysis in hypertensive hypercholesterolemic patients with insulin resistance.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Drug Thera | 2004 |
Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Topics: Age Factors; Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Cerebrovascular Disorders; D | 2005 |
Interaction between amlodipine and simvastatin in patients with hypercholesterolemia and hypertension.
Topics: Administration, Oral; Aged; Amlodipine; Antihypertensive Agents; Drug Interactions; Female; Humans; | 2005 |
Improved attainment of blood pressure and cholesterol goals using single-pill amlodipine/atorvastatin in African Americans: the CAPABLE trial.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Black or A | 2008 |
Synergistic effect of amlodipine and atorvastatin on blood pressure, left ventricular remodeling, and C-reactive protein in hypertensive patients with primary hypercholesterolemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; C-Reactive Protein; Drug Sy | 2008 |
Baseline characteristics of the diabetic participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Ant | 2001 |
19 other studies available for amlodipine and Elevated Cholesterol
| Article | Year |
|---|---|
Impact of simultaneous management of hypertension and hypercholesterolemia with ACE inhibitors and statins on cardiovascular outcomes in the Brisighella Heart Study: A 8-year follow-up.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Atorvastatin; Blood P | 2022 |
Who benefits from fixed-dose combinations? Two-year statin adherence trajectories in initiators of combined amlodipine/atorvastatin therapy.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Australia; Blood Pressure; Drug | 2017 |
Treatment of Hypertensive and Hypercholesterolaemic Patients with the Triple Fixed Combination of Atorvastatin, Perindopril and Amlodipine: The Results of the CORAL Study.
Topics: Adult; Aged; Aged, 80 and over; Amlodipine; Animals; Anticholesteremic Agents; Antihypertensive Agen | 2019 |
[One year persistence of atorvastatin and amlodipine fixed dose combination versus atorvastatin therapy].
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cholesterol, LDL; Dr | 2016 |
Safety and effectiveness of combined antihypertensive and cholesterol-lowering therapy in high-/very high-risk patients.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Cholesterol; Humans; Hypercholesterol | 2016 |
Is Time an Important Problem in Management of Hypertension and Hypercholesterolemia by Using an Amlodipine-Atorvastatin Single Pill Combination?
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Atorvastatin; Blood Pressure; Case-Control Studies | 2016 |
Impact of Statin Therapy on the Blood Pressure-Lowering Efficacy of a Single-Pill Perindopril/Amlodipine Combination in Hypertensive Patients with Hypercholesterolemia.
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Biomarkers; Blood Pressure; Calcium Channel Bl | 2017 |
Cardiac hypertrophy during hypercholesterolemia and its amelioration with rosuvastatin and amlodipine.
Topics: Amlodipine; Animals; Blood Pressure; Body Weight; Calcium Channel Blockers; Cardiomegaly; Cholestero | 2009 |
Amlodipine/Atorvastatin single-pill therapy for blood pressure and lipid goals in African Americans: influence of the metabolic syndrome and type 2 diabetes mellitus.
Topics: Adult; Aged; Amlodipine; Anticholesteremic Agents; Atorvastatin; Black or African American; Blood Pr | 2009 |
Does a single-pill antihypertensive/lipid-lowering regimen improve adherence in US managed care enrolees? A non-randomized, observational, retrospective study.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Calcium Channel Blockers; Drug Therapy, Combination; Female; | 2010 |
Trastuzumab-related palmar plantar erythrodysaesthesia.
Topics: Aged; Amlodipine; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Antihypertensive Agen | 2012 |
Amlodipine attenuates oxidative stress in the heart and blood of high-cholesterol diet rabbits.
Topics: Amlodipine; Animals; Antioxidants; Cholesterol; Diet; Hypercholesterolemia; Oxidative Stress; Rabbit | 2012 |
[Some new data concerning effectiveness of amlodipine, atorvastatine and quinaprile for heart diseases].
Topics: Amlodipine; Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Atorvastatin; Calciu | 2002 |
[Arteriosclerosis: how plaque heals].
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Endothelium, Vascul | 2002 |
Amlodipine and glutathione cycle in hypercholesterolaemia.
Topics: Amlodipine; Animals; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Glutathione; Hypercholeste | 2004 |
Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits.
Topics: Amlodipine; Animals; Antioxidants; Aorta; Atherosclerosis; Calcium Channel Blockers; Cholesterol, Di | 2006 |
Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice.
Topics: Amlodipine; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Atorvastatin; Blood Pres | 2006 |
Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system.
Topics: Acetylcholine; Acridines; Amlodipine; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzym | 1999 |
Laser-assisted optical rotational red cell analyzer (LORCA) in clinical practice. Hemorheological kinetics and tissue oxygenation.
Topics: Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Calcium Channel Blockers; Erythrocyte | 1999 |